Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:DRUG NASDAQ:ENLV NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.50+1.8%$4.43$1.34▼$5.15$617.31M0.761.06 million shs4.32 million shsDRUGBright Minds Biosciences$60.66+1.9%$80.47$23.17▼$123.75$579.26M-5.53442,688 shs239,388 shsENLVEnlivex Therapeutics$0.62+0.6%$0.78$0.61▼$2.10$146.70M1.47436,190 shs323,117 shsTLRYTilray Brands$4.73-0.4%$5.81$3.51▼$23.20$553.61M1.883.41 million shs3.55 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+1.84%+7.80%+0.45%+18.18%+215.71%DRUGBright Minds Biosciences-0.50%-3.31%-20.64%-17.65%+114.95%ENLVEnlivex Therapeutics-1.94%-8.12%-11.37%-42.78%-40.00%TLRYTilray Brands-2.66%-5.38%-8.30%-28.68%+23.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.50+1.8%$4.43$1.34▼$5.15$617.31M0.761.06 million shs4.32 million shsDRUGBright Minds Biosciences$60.66+1.9%$80.47$23.17▼$123.75$579.26M-5.53442,688 shs239,388 shsENLVEnlivex Therapeutics$0.62+0.6%$0.78$0.61▼$2.10$146.70M1.47436,190 shs323,117 shsTLRYTilray Brands$4.73-0.4%$5.81$3.51▼$23.20$553.61M1.883.41 million shs3.55 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+1.84%+7.80%+0.45%+18.18%+215.71%DRUGBright Minds Biosciences-0.50%-3.31%-20.64%-17.65%+114.95%ENLVEnlivex Therapeutics-1.94%-8.12%-11.37%-42.78%-40.00%TLRYTilray Brands-2.66%-5.38%-8.30%-28.68%+23.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.13Buy$11.50155.56% UpsideDRUGBright Minds Biosciences 2.86Moderate Buy$143.83137.11% UpsideENLVEnlivex Therapeutics 2.00Hold$16.502,554.01% UpsideTLRYTilray Brands 2.25Hold$11.50143.13% UpsideCurrent Analyst Ratings BreakdownLatest ENLV, ACRS, TLRY, and DRUG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$13.006/1/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/1/2026DRUGBright Minds Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$145.005/20/2026DRUGBright Minds Biosciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$190.00 ➝ $220.005/13/2026TLRYTilray Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/5/2026ACRSAclaris Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.00 ➝ $11.005/5/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/4/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/29/2026TLRYTilray Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026ACRSAclaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$8.00 ➝ $10.004/16/2026ACRSAclaris Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.00(Data available from 6/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$7.83M80.26N/AN/A$0.85 per share5.29DRUGBright Minds BiosciencesN/AN/AN/AN/A$8.33 per shareN/AENLVEnlivex TherapeuticsN/AN/AN/AN/A$8.15 per shareN/ATLRYTilray Brands$821.31M0.67$1.44 per share3.29$14.04 per share0.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%8/6/2026 (Estimated)DRUGBright Minds Biosciences-$8.74M-$2.44N/AN/AN/AN/A-20.58%-20.25%8/13/2026 (Estimated)ENLVEnlivex Therapeutics$1.24B-$0.55N/AN/AN/AN/A248.08%206.39%8/24/2026 (Estimated)TLRYTilray Brands-$2.19B-$13.65N/AN/AN/A-156.51%-3.31%-2.42%7/27/2026 (Estimated)Latest ENLV, ACRS, TLRY, and DRUG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q2 2026DRUGBright Minds Biosciences-$0.8633-$0.80+$0.0633-$0.80N/AN/A5/7/2026Q1 2026ACRSAclaris Therapeutics-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 million4/1/2026Q3 2026TLRYTilray Brands-$0.14-$0.24-$0.10-$0.24$201.35 million$206.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.034.03DRUGBright Minds BiosciencesN/A81.4781.47ENLVEnlivex TherapeuticsN/A193.24193.24TLRYTilray Brands0.192.791.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%DRUGBright Minds Biosciences40.52%ENLVEnlivex Therapeutics1.02%TLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics4.80%DRUGBright Minds Biosciences42.66%ENLVEnlivex Therapeutics12.28%TLRYTilray Brands0.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100139.66 million132.96 millionOptionableDRUGBright Minds BiosciencesN/A9.73 million5.58 millionNot OptionableENLVEnlivex Therapeutics70237.38 million208.23 millionOptionableTLRYTilray Brands2,842116.55 million115.57 millionOptionableENLV, ACRS, TLRY, and DRUG HeadlinesRecent News About These CompaniesTilray Brands, Inc.: BrewDog Turns Up Father's Day Across the U.K. with Gift-Ready Beer, Custom Cans and Dads Eat Free1 hour ago | finanznachrichten.deTilray Brands, Inc.: Hi*Ball Energy Arrives in the UK, Leading a New Wave of Clean Energy1 hour ago | finanznachrichten.deHi*Ball Energy Arrives in the UK, Leading a New Wave of Clean EnergyJune 18 at 12:09 PM | finance.yahoo.comBreckenridge Distillery Releases Limited Single Barrel Bourbon CollectionJune 18 at 12:09 PM | finance.yahoo.comTilray takes Hi*Ball energy brand to UKJune 18 at 12:09 PM | just-drinks.comJBreckenridge Distillery Releases Limited Single Barrel Bourbon CollectionJune 18 at 7:50 AM | financialpost.comFBreckenridge Distillery Releases Limited Single Barrel Bourbon CollectionJune 18 at 7:30 AM | globenewswire.comHi*Ball Energy Arrives in the UK, Leading a New Wave of Clean EnergyJune 18 at 7:00 AM | globenewswire.comPromising Cannabis Stocks To Follow Now - June 17thJune 18 at 4:05 AM | americanbankingnews.comAltshuler Shaham Ltd Has $857,000 Stock Holdings in Tilray Brands, Inc. $TLRYJune 18 at 3:18 AM | marketbeat.comTilray Brands (NASDAQ:TLRY) Stock Price Down 2.7% - What's Next?June 17 at 5:47 PM | marketbeat.com3 Marijuana Stocks Investors Can See Returns On Before The End Of The YearJune 17 at 1:26 PM | marijuanastocks.comMBrewDog Turns Up Father’s Day Across the U.K. with Gift-Ready Beer, Custom Cans and Dads Eat FreeJune 17 at 9:16 AM | finance.yahoo.comBrewDog Turns Up Father’s Day Across the U.K. with Gift-Ready Beer, Custom Cans and Dads Eat FreeJune 17 at 7:11 AM | financialpost.comFHere's Why Tilray Brands, Inc. (TLRY) Fell More Than Broader MarketJune 16 at 7:38 PM | finance.yahoo.comHere's Why Tilray Brands, Inc. (TLRY) Fell More Than Broader MarketJune 16 at 7:00 PM | zacks.comTilray Brands (NASDAQ:TLRY) Shares Down 2.6% - What's Next?June 16 at 5:46 PM | marketbeat.comBreckenridge Brewery Launches a Colorado-Wide Soccer Celebration with Fan-First ActivationsJune 16 at 9:36 AM | finance.yahoo.comBrewDog USA Brings Summer Soccer to Life with Watch Parties and Fan Events in Las Vegas and Across OhioJune 16 at 9:36 AM | finance.yahoo.comBreckenridge Distillery Celebrates America's 250th Anniversary with the Launch of Patriotic Reserve Bourbon WhiskeyJune 16 at 9:36 AM | finance.yahoo.comBreckenridge Distillery Celebrates America’s 250th Anniversary with the Launch of Patriotic Reserve Bourbon WhiskeyJune 16 at 8:10 AM | financialpost.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENLV, ACRS, TLRY, and DRUG Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$4.50 +0.08 (+1.81%) Closing price 04:00 PM EasternExtended Trading$4.31 -0.19 (-4.20%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Bright Minds Biosciences NASDAQ:DRUG$60.66 +1.14 (+1.92%) Closing price 04:00 PM EasternExtended Trading$64.75 +4.09 (+6.74%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Enlivex Therapeutics NASDAQ:ENLV$0.62 +0.00 (+0.60%) Closing price 04:00 PM EasternExtended Trading$0.64 +0.02 (+3.43%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Tilray Brands NASDAQ:TLRY$4.73 -0.02 (-0.42%) Closing price 04:00 PM EasternExtended Trading$4.74 +0.00 (+0.11%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI CoreWeave Insider Sales Look Big, But Should Investors Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
